Form 4: Redmile Group Acquires Pre-Funded Warrants in Fate Therapeutics Public Offering

Redmile Group, through managed investment vehicles, acquired pre-funded warrants to purchase 3,636,364 shares of Fate Therapeutics common stock in a private placement concurrent with a public offering.

Summary

• Redmile Group, LLC, along with Jeremy Green, filed a Form 4 detailing changes in beneficial ownership of Fate Therapeutics Inc. securities.
• On March 21, 2024, Redmile acquired pre-funded warrants to purchase 3,636,364 shares of Fate Therapeutics common stock.
• The pre-funded warrants were acquired in a private placement concurrent with an underwritten public offering of Fate Therapeutics common stock.
• The purchase price for the pre-funded warrants was $5.50 less $0.001 per warrant.
• The warrants are exercisable at any time after the closing date of the purchase agreement at an exercise price of $0.001 per share.
• The warrants are subject to a 9.99% beneficial ownership blocker and limitations based on Nasdaq rules.
• Redmile and Jeremy Green disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• Michael Lee, a Redmile managing director, is a Fate Therapeutics board member, making Redmile and Green directors by deputization.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a regulatory filing detailing a transaction. While the investment by Redmile is a positive signal, the document itself is factual and doesn't convey strong positive or negative sentiment.

Positives

• The acquisition of pre-funded warrants represents a further investment by Redmile Group in Fate Therapeutics.
• The warrants are exercisable at a nominal price of $0.001 per share, providing potential upside for Redmile.
• The absence of an expiration date on the warrants provides flexibility for Redmile.

Risks

• The 9.99% beneficial ownership blocker could limit Redmile's ability to exercise all warrants.
• Nasdaq rules could further restrict the issuance of shares upon warrant exercise.
• Redmile and Jeremy Green disclaim beneficial ownership, potentially limiting their influence.

Future Outlook

The document does not contain explicit forward-looking statements, but the acquisition of warrants suggests a continued interest in Fate Therapeutics by Redmile Group.

Management Comments

• Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
• This report shall not be deemed an admission that the Reporting Persons are a beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

The investment by Redmile Group in Fate Therapeutics, a company focused on cell-based cancer immunotherapies, reflects ongoing investor interest in the biotechnology sector, particularly in companies developing innovative therapies.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the exact terms of the public offering and the private placement.
• However, private placements of warrants are a relatively common financing tool in the biotech industry, particularly for companies that are still in the development stage.
• Comparable companies that have used similar financing strategies include companies such as CRISPR Therapeutics and Editas Medicine, although the specific terms of their financings may differ.

Stakeholder Impact

• The investment by Redmile Group could be viewed positively by shareholders, potentially increasing investor confidence.
• The capital raised through the public offering and private placement will likely be used to fund Fate Therapeutics' research and development activities.

Key Dates